Major histology subtypes in NSCLC1

Percent distribution of stage IIIB-IV NSCLC patients receiving first-line
therapy by histology2a

Incidence of adenocarcinoma, squamous, and large cell subtypes of non-small cell lung cancer
aEstimates based on Kantar Health Patient Metrics; 2014.
bOthers includes large cell carcinoma, non-small cell carcinoma, other specified carcinomas.

Major histology subtypes in NSCLC1

Percent distribution of stage IIIB-IV NSCLC patients receiving first-line therapy by histology2a

Incidence of adenocarcinoma, squamous, and large cell subtypes of non-small cell lung cancer

The majority of NSCLC patients do not have an actionable biomaker3,4

aEstimates based on Kantar Health Patient Metrics; 2014.
bOthers includes large cell carcinoma, non-small cell carcinoma, other specified carcinomas.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.